Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Efsubaglutide Alfa

The Efficacy and Safety of Efsubaglutide Alfa Injection in Overweight and Obese Subjects (ENLIGHT)

Shanghai Yinnuo Pharmaceutical Technology Co · Phase 2/3 · Active, not recruiting · Enrollment 1003

NCT06921486

ArmPopulationDoseWeeksEstimandWeight change
Phase IIb:Efsubaglutide Alfa 5 mg QWObesity or overweight5 mg3n/rn/r
Phase IIb:Efsubaglutide Alfa 10 mg QWObesity or overweight10 mg3n/rn/r
Phase IIb:Efsubaglutide Alfa 20 mg QWObesity or overweight20 mg3n/rn/r
Phase IIb:Efsubaglutide Alfa 20 mg Q2WObesity or overweight20 mg3n/rn/r
Phase IIb:PlaceboObesity or overweightn/r3n/rn/r
Phase III:Recommended Phase 3 Dose (RP3D) Low Dose QWObesity or overweightn/r3n/rn/r
Phase III:Recommended Phase 3 Dose (RP3D) High Dose QWObesity or overweightn/r3n/rn/r
Phase III:Recommended Phase 3 Dose (RP3D) High Dose Q2WObesity or overweightn/r3n/rn/r
Phase III:PlaceboObesity or overweightn/r3n/rn/r